- APTO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Aptose Biosciences (APTO) 8-K30 Aug 24Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patientsFinancial data
Company Profile